Compare NBTB & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | TYRA |
|---|---|---|
| Founded | 1856 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 1995 | 2021 |
| Metric | NBTB | TYRA |
|---|---|---|
| Price | $46.33 | $33.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $51.33 | $47.50 |
| AVG Volume (30 Days) | 265.1K | ★ 626.1K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $182,952,000.00 | N/A |
| Revenue This Year | $16.82 | N/A |
| Revenue Next Year | $4.88 | N/A |
| P/E Ratio | $47.09 | ★ N/A |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $39.21 | $8.98 |
| 52 Week High | $46.92 | $40.65 |
| Indicator | NBTB | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 44.88 |
| Support Level | $41.66 | $31.45 |
| Resistance Level | $46.68 | $33.99 |
| Average True Range (ATR) | 0.89 | 1.87 |
| MACD | 0.13 | -0.15 |
| Stochastic Oscillator | 85.20 | 22.08 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.